Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 0

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 0
---
Item 1.	Business 

Company and Business Strategy Overview

As a global healthcare holding company, with operations in South Korea
and Switzerland and an office in the United States, we intend to leverage our existing and expanding network of academic and industry
leaders and investor network, including venture capital and private equity, in major healthcare markets globally to identify, lead and
support the growth of our subsidiaries and subsidiary candidates based on innovative research. Subsidiary candidates are companies that
are either already existing entities or new companies formed in connection with acquiring or licensing existing assets from pharmaceutical
firms. We expect to attract industry partners either as co-investors or through technology licensing deals and may raise capital
directly from private, strategic or public investors. We seek to chart a potentially more efficient and optimal route by pairing what
we believe are the right team and pharmaceutical or medical device technologies that have the potential to treat diseases and improve
healthcare outcomes with the necessary financial and other resources. Since our target markets feature large established global businesses
with abundant capital that acquire healthcare companies, we hope to realize additional liquidity through the sale of our subsidiaries
from time to time.

We are a data-driven company. We evaluate our subsidiary candidate
opportunities by better understanding the target indications toward identifying new approaches and technologies to improve treatment outcomes.
We collaborate with academic and industry leaders to promote a seamless integration and partnership between entrepreneurial scientists
and seasoned business development and leadership teams. These technical and scientific experts from academia and industry bring innovative
contributions and a high level of enthusiasm. Our holding company leadership team supports and empowers each subsidiary to transform their
potentially breakthrough discoveries into impactful and viable commercial products.

Our company’s collective expertise from industry veterans, seasoned
scientists, capital market and legal professionals provides the core foundation of our global healthcare holding company. the Company
operates as a hub-and-spoke business model with a centralized executive team partnering with subsidiary management teams to ensure
overall program and corporate alignment by and between subsidiaries and holding company. Our overarching goal is to enhance value creation
for our subsidiaries by continuously assessing optimal development options and exploring partnership and fundraising opportunities. We
encourage cooperation and knowledge sharing among our subsidiaries to enhance our synergistic business model. We believe our strong foundational
scientific conviction, entrepreneurial acumen and opportunistic approach positions us as a differentiated global company advancing pharmaceutical
and medical device technologies in an efficient, cost-effective and meaningful manner. Our interdisciplinary team of accomplished
scientists and entrepreneurial business leaders